Get it on Google Play

Celgene (CELG) Granted FDA Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer

May 23, 2013 7:33 AM EDT Send to a Friend
Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that the U.S. Food and Drug Administration (FDA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login